U.S.-China Heparin Scare Could Affect Indian Drug Makers
This article was originally published in PharmAsia News
Executive SummaryThe scare surrounding tainted Chinese heparin could have an impact on Indian drug makers. The discovery that the active ingredient in blood-clotting drugs was tainted by Chinese suppliers has increased quality concerns by U.S. firms that obtain ingredients from China and India. Indian firms may be tempted to dismiss the concern as a problem China must deal with, but India often is mentioned as part of a general problem with sources of ingredients. One U.S. drug consultant says many companies are looking to Indian sources to replace Chinese sources, likely adding to U.S. scrutiny. (Click here for more
You may also be interested in...
ConMed’s ambitions in orthopedics are to be the clinician’s support, develop differentiated offerings and avoid “me too” activity, before all notions of leading the market rankings.
Executives On The Move: Tech And Science Announcements At Orexo And Agios, And Board Changes At Accorda And RhoVac
Swedish pharma Orexo welcomes EVP, digital health and anti-cancer therapeutics firm Agios Pharmaceuticals announces Bristol-Myers Squibb exec as its next CSO. And a chair takes a seat at Accorda Therapeutics and RhoVac.
In 2018, the top 100 publicly listed and reportable medical device technology companies had global sales spanning from over $30bn to some $100m in the lower reaches. As the latest In Vivo Medtech 100 ranking shows, many of the major changes in value sales were linked to company restructurings. But there were some impressive organic gains too.